How should I prescribe albuterol (salbutamol) rescue inhaler and inhaled fluticasone for a pediatric asthma patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

How to Prescribe Albuterol and Fluticasone Inhalers for Pediatric Asthma

For pediatric asthma patients, prescribe albuterol as a rescue inhaler (1-2 puffs every 4-6 hours as needed for symptoms) and fluticasone as a daily controller medication dosed twice daily based on age-specific dosing ranges, with the child using a spacer device with face mask (if under 4 years) and instructed to rinse mouth after each fluticasone dose.

Albuterol (Rescue Inhaler) Prescribing

Dosing by Age 1, 2:

Children under 5 years:

  • MDI: 1-2 puffs every 4-6 hours as needed for symptoms
  • Nebulizer solution: 0.63 mg/3 mL for children <15 kg; 1.25-2.5 mg for children ≥15 kg
  • Must use with spacer device and face mask

Children 5-11 years:

  • MDI: 2 puffs every 4-6 hours as needed
  • Nebulizer solution: 1.25-5 mg in 3 mL saline

Critical Prescribing Instructions 1:

  • Not for daily maintenance therapy - regular use exceeding 2 days/week for symptom control (excluding exercise-induced bronchospasm prevention) indicates poor asthma control requiring reassessment
  • Increasing use or lack of expected effect signals worsening asthma requiring immediate medical attention 2
  • For acute exacerbations: 4-8 puffs every 20 minutes for 3 doses via MDI with spacer, then every 1-4 hours as needed 1, 3

Fluticasone (Controller Inhaler) Prescribing

Age-Specific Dosing 1:

Children 0-4 years (Fluticasone HFA):

  • Low dose: 176 mcg/day (divided twice daily)
  • Medium dose: >176-352 mcg/day (divided twice daily)
  • High dose: >352 mcg/day (divided twice daily)
  • Requires face mask with spacer; higher doses needed in this age group due to lower delivery efficiency

Children 5-11 years (Fluticasone HFA/MDI: 44,110,220 mcg/puff):

  • Low dose: 88-176 mcg/day (divided twice daily)
  • Medium dose: >176-352 mcg/day (divided twice daily)
  • High dose: >352 mcg/day (divided twice daily)

Children 5-11 years (Fluticasone DPI: 50,100,250 mcg/inhalation):

  • Low dose: 100-200 mcg/day (divided twice daily)
  • Medium dose: >200-400 mcg/day (divided twice daily)
  • High dose: >400 mcg/day (divided twice daily)

Essential Administration Instructions 1:

  • Always divide total daily dose into twice-daily administration (morning and evening)
  • Mandatory spacer/valved holding chamber for non-breath-actuated MDIs in all children
  • Face mask required for children <4 years to ensure adequate delivery
  • Wash face after each treatment to prevent local side effects (oral thrush, dysphonia)
  • Rinse mouth and spit after inhalation to decrease oral candidiasis risk

Device Selection Algorithm

For children <4 years: Nebulizer or MDI with spacer and face mask only 1

For children 4-11 years: MDI with spacer preferred; DPI acceptable if child can generate sufficient inspiratory flow 1

For children ≥12 years: MDI with spacer or DPI based on patient preference and technique

Common Pitfalls to Avoid

  1. Prescribing albuterol for regular daily use - This indicates inadequate controller therapy and increases mortality risk 1

  2. Omitting spacer device prescription - Spacers are essential for proper drug delivery and reducing systemic absorption in children 1

  3. Not prescribing face mask for children <4 years - Face mask is mandatory for adequate fluticasone delivery in young children 1

  4. Single daily dosing of fluticasone - Must be divided twice daily for optimal efficacy 1

  5. Failing to educate about mouth rinsing - This simple step significantly reduces oral candidiasis risk 1

  6. Not monitoring growth velocity - Low-to-medium dose ICS may cause transient growth suppression in children, requiring monitoring 1

Drug Interactions to Consider

Fluticasone is metabolized by CYP3A4 enzymes 1. Potent CYP3A4 inhibitors (ritonavir, ketoconazole) can increase systemic fluticasone concentrations, potentially causing Cushing syndrome or adrenal insufficiency. Avoid concurrent use or use lowest effective fluticasone dose with close monitoring.

Sample Prescription Format

Albuterol HFA 90 mcg/puff:

  • Sig: Inhale 2 puffs every 4-6 hours as needed for wheezing, shortness of breath, or chest tightness. Use with spacer device. If needing more than 2 days/week, contact provider.
  • Dispense: 1 inhaler (200 puffs)
  • Refills: 3

Fluticasone HFA 44 mcg/puff (for 5-11 year old with mild persistent asthma):

  • Sig: Inhale 2 puffs twice daily (morning and evening) with spacer device. Rinse mouth and spit after each use. Do not stop without consulting provider.
  • Dispense: 1 inhaler
  • Refills: 5

References

Related Questions

A 41-year-old male with a long-standing diagnosis of asthma is now using his albuterol (short-acting β2‑agonist) inhaler daily; what are the next steps in management and should he be referred to a pulmonologist?
Is it appropriate to prescribe an additional three‑day course of oral prednisolone together with home albuterol (salbutamol) nebulizer treatments for a 5‑year‑old child with asthma who has had a week of cough, received a three‑day course of prednisolone with partial improvement, and now has scattered wheezing on the right lung?
In a 23-year-old patient with suspected exertional asthma who has not yet been evaluated, is it appropriate to prescribe albuterol (short‑acting β2‑agonist) while awaiting pulmonology referral?
In a 16-year-old female using albuterol (short-acting β2-agonist) who feels winded when climbing stairs, what is the appropriate next step in management?
Which rescue inhaler (Airsupra – albuterol and budesonide) and steroid regimen should I use for a PPD‑related flare?
How should prone positioning be safely performed in pediatric patients receiving enteral nutrition, including aspiration risk mitigation and feeding tube management?
In this patient, should we prescribe only propranolol, or is metoprolol an acceptable alternative beta‑blocker?
What are the differential diagnoses for a 70-year-old woman with a white blood cell count of 32,100/µL and a differential of 71% neutrophils, 11% band forms, 2% lymphocytes, and 1% monocytes?
After increasing the lithium dose, when should I recheck the serum lithium concentration?
Is there literature supporting an increased aspiration risk for patients in the prone position receiving enteral tube feeding?
When should a serum digoxin level be drawn in an outpatient setting after initiating digoxin therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.